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Two Years after Pandemic Influenza A/2009/H1N1: What Have We Learned?
INTRODUCTION P revious pandemic influenza viruses involved an antigenic shift to a different subtype. However, the antigenic shift demonstrated by the pandemic influenza A H1N1 2009 virus (A/2009/ H1N1) was an antigenic change from a human H1N1 subtype to a swine H1N1 subtype. Pig surveillance programs have not been able to detect the immediate precursor of this virus in pigs in South China and other parts of the world (51) . Although South China was predicted to be the starting point of influenza pandemics, the first human case and the initial epidemic were detected in North America and Mexico, respectively (140, 184) . Unlike the poor predictability of pig surveillance, human seroepidemiology correctly predicted an impending pandemic due to the lack of immunity in the general population with relative protection in the elderly (387) . However, seroepidemiology and laboratory studies were unable to make an accurate assessment of the disease severity in order to recommend a commensurate pandemic alert level. Regarding the risk factors for severe disease, obesity was an important predisposing factor, in addition to extremes of age, pregnancy, and underlying medical illness (364, 458, 522) . In patients with severe disease, viral clearance was delayed, with a persistent elevation of proinflammatory cytokines and associated multiorgan damage despite antiviral therapy (510) . Additionally, a lower serum IgG2 level appeared to be associated with disease severity, especially in pregnant patients (80, 207) . Severe disease and lung pathology were associated with immune complex deposition. In terms of laboratory diagnosis, a comparative laboratory test eval-uation showed that a rapid diagnosis was best achieved by reverse transcription-PCR (RT-PCR), which was markedly superior to antigen detection by enzyme immunoassays (EIAs) (296) . None of the viral genomic signatures, such as PB2-K627, full-length PB1-F2, and the PDZ motif of NS1, which were previously speculated to be useful in predicting the virulence of the influenza A virus were present in this pandemic virus (293) . Only the hemagglutinin D222G (H1 numbering) mutation with a predilection for ␣-2,3-linked sialic acid was associated with clinically severe disease and the involvement of the lower respiratory tract (96) . In addition, the similar crystal structures, antigenic makeups, and patterns of glycosylation for the hemagglutinin of this virus and that of the 1918 virus explained the relative protection of the elderly through the induction of crossreactive humoral and cellular immune responses against the surface and internal proteins, respectively. As for treatment options, the intrinsic resistance to adamantanes leaves the early initiation of neuraminidase inhibitors as the only option available in most countries. Moreover, further mutations may affect the usefulness of these antivirals. In severe cases, intravenous peramivir or zanamivir, convalescent-phase plasma, and hyperimmune intravenous immunoglobulin can be considered in clinical trial settings. Despite the technological advances in using cell-based inactivated whole-virus vaccines and improved adjuvants, vaccine production failed to prevent the first peak in tropical areas and the Southern Hemisphere. The bottlenecks for the rapid mass production of vaccines must be overcome before the next pandemic. Social distancing methods, such as canceling entertainment and sporting events, closing stores, office buildings, and public transportation systems, border screening, the isolation and quarantine of febrile patients and contacts, school closures, and hospital infection control measures may achieve only a few more weeks of preparedness by slowing down the introduction and spread of the pandemic virus if instituted early enough. In this article, we review the biology of the virus in relation to the clinical manifestations, pathogenesis, laboratory diagnosis, host susceptibility, immune response, and options for treatment, immunization, public health, and infection control. Because there have been a large number of publications on this topic, we can select only those publications related to the understanding and practice of clinical microbiology and infectious diseases.
TAXONOMY, NOMENCLATURE, AND GENERAL VIROLOGY
The influenza virus is a negative-sense, single-stranded RNA virus with a lipid-containing envelope and an eight-segment genome encoding 11 or 12 proteins (545) . The pleomorphic viral particles observed in cell culture or clinical specimens may vary from spherical to filamentous in shape, with a diameter of 120 nm. The A/2009/H1N1 virus produces filamentous viral particles when grown in cell lines examined by electron microscopy (274) . This virus belongs to the family Orthomyxoviridae, which includes the genera of influenza virus, Thogoto virus, and infectious salmon anemia virus (155, 424) . The genus of influenza virus is divided into types A, B, and C as defined by the antigenicity of the nucleocapsid and matrix proteins in the viral core (424) . These proteins are the antigens used in the complement fixation test for typespecific antibodies (250) . Among the three genera, the influenza A virus is associated with more severe disease and pandemics in humans (234, 569) . The influenza A virus is further subtyped by two surface proteins, hemagglutinin (H), which attaches the virion to the host cell for cell entry, and neuraminidase (N), which facilitates the spread of the progeny virus by cleaving the host sialic acid receptors attached to the progeny virus (137) . There are 16 H subtypes and 9 N subtypes, which make up all of the subtypes of the influenza A virus by various combinations of H and N (180) . The infidelity of RNA polymerase (one mutation per genome per replication) and the selective pressure of host immunity lead to the accumulation of mutations and a change in the surface antigenicity of these surface proteins, which are the targets of neutralizing and hemagglutination-inhibiting antibodies (2) . This antigenic change is called antigenic drift (424) . Thus, every year in February, the World Health Organization (WHO) selects the strains of virus that are to be used for the annual influenza vaccination in humans according to this antigenic drift. The nomenclature of the viral strain is written in the following order: type/ place of isolation/strain number/year of isolation(subtype). Using the year 2005 as an example, the WHO recommended changing the virus strain from influenza A/Fujian/411/2003(H3N2) to A/California/7/2004(H3N2) for vaccination purposes. These changes are necessary because the hemagglutination inhibition antibody titers in the general population that would be induced by the older vaccine strain would not be sufficient to provide good protection against a newly drifted or, in the case of a pandemic, newly shifted strain (429) . All of the combinations of the 16 H and 9 N viral subtypes are found in water fowl, whereas the H1 to H3 and N1 and N2 viral subtypes are commonly found in humans infected with influenza (4) . Because of its segmented genome, the shuffling of gene segments can occur if two different subtypes of the influenza A virus infect the same cell. This genetic reassortment of the gene segments from different animals can lead to a major surface antigenic change, resulting in a new reassorted virus to which the global population has no effective neutralizing antibodies. A pandemic may ensue if this new virus has preserved replicative efficiency in human cells and transmissibility between humans.
A phylogenetic analysis of the A/2009/H1N1 virus suggested that the ancestors of the 8 gene segments are different and can be traced to avian, human, and swine origins (481) . In previous pandemic viruses, the H subtypes shifted from H1 to H2 in 1957 and H2 to H3 in 1968, whereas the 2009 pandemic virus had North American swine H1 and Eurasian swine N1, replacing the circulating human seasonal H1N1 virus subtype (472) . Using all of the available H1N1 virus sequences in GenBank, phylogenetic analysis suggested that the A/2009/H1N1 virus strains, and the 1976 New Jersey swine strains, and the 1918 pandemic H1N1 strains are distinct and diverge from the human seasonal H1N1 strains circulating since 1918 (Fig. 1 ). This form of genetic shift is different from those of the 1957 pandemic H2N2 virus, which evolved from the circulating H1N1 virus by acquiring the H2, N2, and PB1 genes from avian species (301) , and the 1968 pandemic H3N2 virus, which is likely to have evolved from the circulating H2N2 virus by acquiring the H3 and PB1 genes from avian species (173, 301) . Thus, animal surveillance programs for influenza virus will continue to play an important role in the detection of the immediate precursor virus in animals before it becomes a pandemic virus in humans. However, the vast geographic distribution of pig and poultry farming, especially in developing countries, presents an enormous challenge for surveillance programs to detect such a precursor virus before a pandemic begins.
The 8 gene segments of the influenza A virus genome, encoding 11 to 12 viral proteins with various functions in the life cycle, often serve as antiviral and diagnostic targets (Fig. 2) . Three gene segments encode the polymerase proteins PB1, PB2, and PA and two smaller proteins, PB1-F2 and N40. The polymerase proteins are antiviral targets of ribavirin, viramide, and T-705 (141, 312) . PB2 is necessary for cap binding and endonuclease activity but can also inhibit the induction of type I interferon (276) . PA functions as an RNA polymerase subunit and in proteolysis (441) . PB1-F2 is a mitochondrial toxin that causes cellular apoptosis and inhibits the induction of type I interferon (524) . Additionally, a newly identified protein of unknown function, N40, is expressed from the PB1 fragment (545) .
Nucleoprotein (NP) can be an antiviral target of nucleozin and its analogs (295) . NP is the structural component of ribonucleoprotein (RNP). H is the target for neutralizing antibodies and has a precursor form called HA0 that undergoes proteolytic cleavage into two components, HA1 and HA2. HA1 functions in the attachment of the virus onto the sialic acid receptor, and HA2 is responsible for membrane fusion. H has 4 major antigenic domains, with frequent mutations in 5 hypervariable regions at HA1. N is the antiviral target of oseltamivir, zanamivir, and peramivir (243) . N serves as a sialidase that is required for the release of progeny virions (425) . N binds plasminogen for the activation of H by proteolytic cleavage (208) . The matrix protein M1 is a structural protein for the nuclear export of viral RNA (vRNA) and viral budding, whereas M2 functions as an ion channel for the acidification of the viral core during the uncoating of virus in endosomes. M2 is the antiviral target of the adamantanes, which include amantadine and rimantadine. In addition, M2 induces heterotypic antibodies associated with protection. The nonstructural protein NS1 is an interferon antagonist that may also stimulate proinflammatory cytokines in infected cells, whereas NS2 is a nuclear export factor.
In addition to the spikes in the H and N proteins that cover the surface of the virion (402) , the M2 protein is embedded in the lipid envelope with its ectodomain exposed on the surface (444) . Below the lipid envelope is a layer of the M1 protein that surrounds the RNP core (573) . The core consists of 8 RNA segments that are associated with one or more copies of the viral polymerase complex and covered by NP molecules (16) . Recent studies suggested that the genetically highly conserved M2 ectodomain and the stalk region of HA2 could be the antigenic targets of neutralizing antibodies for the production of a universal influenza A vaccine (37, 483) . Glycosylation has been associated with the masking of epitopes on H, and the A/2009/H1N1 virus has significantly reduced glycosylation compared to the previous seasonal influenza H1N1 virus (563) . This finding may partly explain why a single dose of the A/2009/H1N1 vaccine was sufficient enough to induce immunity in immunologically naïve individuals.
The pandemic influenza virus behaves like other influenza viruses, which are infectious for more than 24 h under low (Ͻ25%) and high (Ͼ80%) relative humidity but less stable at intermediate humidity (50%) and higher temperatures (366, 490) . Thus, the virus should be most stable in cold winters. Unexpectedly, the A/2009/H1N1 virus emerged in the spring in North America and spread during the summer in tropical areas and the Southern Hemisphere. This virus produced a larger second wave during the early autumn in the Northern Hemisphere. Thus, the pressure of seasonality on transmission was overwhelmed by the lack of herd immunological control. The virus can be readily inactivated by detergents, disinfectants, ionizing radiation, or temperatures greater than 50°C (287) .
VIRAL LIFE CYCLE
The virus initiates its life cycle when H attaches to the receptors on a cell surface that contains sialic acid, such as glycolipids or membrane glycoproteins. Human influenza viruses, including the A/2009/H1N1 virus, preferentially bind to sialic acid with an ␣-2,6-linkage to galactose, which contains oligosaccharides that are abundantly present in the upper respiratory tract (473) . In contrast to the other human seasonal influenza A/H1N1 virus, the A/2009/H1N1 virus also binds to the ␣-2,3-linked sialic acid receptors that are present in the lower respiratory tract (113) . The internalization of the virus into endosomes occurs by endocytosis, which is mediated by epsin-1, a cargo-specific adaptor for virus entry through the clathrin-mediated pathway or by the clathrinindependent pathway (91) . The precursor polypeptide HA0 must be activated by proteolytic cleavage into HA1 and HA2 by trypsin or a trypsin-like endogenous host cell protease before it can undergo an acid pH-triggered conformational change into a fusogenic form (97) . Then, the viral and endosomal membranes can be fused. The ion channel M2 in the viral membrane is then activated by endosomal acid pH, resulting in an influx of protons into the virion and the dismantling of M1 from the RNP core (465) . The dismantling process will release the RNP into the cytoplasm. PB2 and NP both have a nuclear localization signal (NLS) and can bind to importin ␣ 1 (a cellular nuclear import factor), the most abundant importin in human cells (189) . Next, the RNP enters through the nuclear pore into the nucleus, where the transcription and replication of the viral genome occur (254) . This nuclear localization of influenza virus NP results in the egg yolk appearance of an infected cell that is stained by an immunofluorescent antibody against the NP in clinical specimens, such as nasopharyngeal aspirate. Moreover, blocking the trafficking of the viral NP from the cytoplasm into the nucleus by nucleozin analogs was shown to be a viable antiviral mechanism (295). The nuclear viral RNP then becomes the template for the production of mRNA that snatches its 5= cap of 9 to 15 nucleotides from host mRNA (320, 460) . In addition, this viral RNP is the template for the full-length complementary copy that becomes a template for the amplification of viral RNA genomes. With an NLS, viral PB1, PB2, PA, and NP are transported into the nucleus, where they associate to form RNP (290, 397, 406, 413) . Both vRNA and cRNA complexed with RNP have a panhandle/fork/corkscrew structure (178) . The export of viral RNP back to the cytoplasm depends on M1, which binds to the RNP and interacts with NS2, which has a nuclear export signal (471) . Under the cytoplasmic membrane, the RNP-M complex assembles under patches of H and N to form virions (499) . The packaging of vRNA in viral particles depends on the 3= and 5= noncoding regions with cis-acting signals (268) . Additionally, the coding sequences of the viral RNA contribute to the efficient packaging, but the exact mechanism is unknown (401) . The budding of infectious progeny virions is followed by their release from their aggregation by their viral H bound to sialic acid, which is mediated by the sialidase activity of N. Because the mRNAs of H, M, NP, and NS are more abundantly expressed than the PA, PB1, PB2, and N genes, RT-PCR diagnostic tests are often targeted against the M gene, which is abundant and genetically conserved, and the H gene, which is abundant and subtype specific (153, 331, 447) . The most abundant protein that is expressed in infected cells and constitutes the structure of a free virion is the NP (448) . Thus, most EIAs for the influenza virus antigen are targeted toward the NP, which is type specific, but these tests cannot differentiate between subtypes.
CELL ENTRY AND VIRULENCE FACTORS
Virus-containing droplets may settle on nasopharyngeal, tracheobronchial, conjunctival, or other respiratory mucosal epithelia. The virus moves randomly through the mucus layer of the mucosa with the aid of neuraminidase to find the appropriate cell receptor for binding by viral H. The ␣-2,6-linked sialic acid receptors are present in both the upper and lower respiratory tracts of humans, the latter of which are lined by tracheobronchial pseudocolumnar epithelium and type 1 pneumocytes. The ␣-2,3-linked sialic acid receptors are present in the distal bronchiole, type 2 pneumocytes, and alveolar macrophages of humans (473) . The H of the A/2009/ H1N1 virus adheres to the ␣-2,6-linked sialic acid receptors and to the ␣-2,3-linked sialic acid receptors, which are more highly expressed in the human lower respiratory tree. The latter binding affinity is similar to that of the H subtypes of the avian influenza A virus, such as the H5N1, H9N2, or H7N7 subtype, which also preferentially attach to the ␣-2,3-linked sialic acid receptors that are present on the respiratory and alimentary epithelia of birds, human conjunctiva, and the ciliated portion of human respiratory pseudostratified columnar epithelium; therefore, this binding affinity allows for the sporadic jumping of avian influenza viruses into humans (Fig. 3) . Moreover, this binding affinity allows the A/2009/H1N1 virus to infect and replicate to high titers in the lungs of ferrets, mice, and monkeys, with a greater proinflammatory response than for seasonal influenza virus. Nevertheless, the damage caused by the A/2009/H1N1 virus is less than that of the H5N1 virus (274, 369, 400, 520) . This finding may partially explain the predilection of this new virus to cause pneumonia in healthy individuals (113) . However, this in vitro glycan binding phenomenon has not been replicated in other studies (41, 99, 354, 369, 564, 567) .
In addition to its pathogenetic significance, the differential binding affinity of H for different receptors affects the evolution of influenza virus. The respiratory epithelium of pigs contains both ␣-2,6-and ␣-2,3-linked sialic acid receptors; therefore, pigs can be infected by human, swine, and avian influenza viruses. Because pigs live in close proximity to humans and poultry in residential backyards in Southeast Asia, they can theoretically serve as "mixing vessels" for gene reassortment between avian, swine, and human influenza viruses, which may create future pandemics.
The conserved amino acid residues within the influenza virus H receptor binding site that are implicated in receptor specificity include amino acid positions 98, 136, 153, 183, 190, 194, 222, 225, 226, 227, and 228 . Remarkably, the only difference between the 1918 H1 of the A/New York/1918/H1N1 virus and an avian H consensus receptor binding signature is a single E190D mutation (H3 numbering) (476) . The H crystal structure of the A/2009/ H1N1 virus reveals a close resemblance to the 1918 H1N1 virus (563) . The H1 of the A/South Carolina/1918/H1N1 virus has an additional G225D (H3 numbering) substitution, which is sufficient to switch the receptor preference from ␣-2,3 to ␣-2,6 in cell-based assays (501) . The A/2009/H1N1 virus possesses a "human virus"-type amino acid at positions 190 and 225 (222 by H1 numbering), which most likely supports the efficient transmissibility of these viruses in humans. In addition to these two positions, a difference in only two other amino acids, at positions 200 and 227, differentiated the receptor binding specificities of the swine H1 virus and the pandemic H1 virus (149) . When the A/2009/H1N1 virus was compared with the classical swine virus, the most discriminative positions were all located in the receptor binding pocket, suggesting that these positions may be important in the human adaptation of the virus (386) . Interestingly, some isolates from patients with severe disease, especially in lower respiratory tract specimens, possess an amino acid substitution at position D222G (H1 numbering) (96) , and D222G is associated with viremia (516) . The D222G mutant has been readily generated in mouse adaptation experiments that demonstrated a significant increase of virulence in mice (580) . Additionally, the D222G mutant has been shown to have stronger binding to turkey erythrocytes than wild-type virus (85) . Homology modeling and molecular docking showed that the receptor binding pocket of the A/2009/H1N1 virus is smaller than those of other influenza A viruses, which allows for a tighter binding of the virus with the receptor. The amino acid at position 222 of H may affect the positioning of the conserved Q223 residue, hence modulating the flexibility of the binding pocket and steric hindrance during receptor binding. In addition, the molecular property of residue 222 can directly influence the "lysine fence" via the polarity of the amino acid residue, where the D222G substitution enhances the electrostatic interactions between the receptor and the protein (515) . Furthermore, the lysine fence at the H of the A/2009/H1N1 virus, which is a positively charged structure composed of K145, K133, and K222, favors the binding of the virus to both ␣-2,3-and ␣-2,6-glycans (487) .
Viruses that possess PB2-K627 but not viruses that possess PB2-E627 were previously observed to grow efficiently in the upper respiratory tracts of mammals (241) , which suggests that PB2-K627 confers efficient replication at 33°C (the temperature of the upper airway in humans), whereas PB2-E627 does not. In contrast, both variants mediate efficient replication at 37°C. Collectively, these findings suggest that PB2-K627 allows for efficient replication in the lower and upper respiratory tracts of mammals, a feature that may facilitate transmission. Notably, the replacement of PB2-K627 with glutamic acid reduced the transmissibility of human influenza viruses in a guinea pig model (489) . In addition, the amino acid substitution at position 701 of PB2 has emerged as a determinant of virulence, a role probably related to its facilitation of the binding of PB2 to importin in mammalian cells. The recently emerged A/2009/H1N1 virus possesses "lowpathogenic"-type amino acids at positions 627 and 701, i.e., glutamic acid and aspartic acid, respectively (426) . However, these low-virulence pathotypes may be overcome by PB2-R591, which has been shown to confer efficient replication of the virus (566) .
Other virulence-associated genomic signatures, such as the full-length PB1-F2, the cleavage and polyadenylation specificity factor 30-kDa subunit (CPSF30), the E92 and PDZ domains of NS1, and the multibasic H cleavage sequence, which were previously speculated to be useful in predicting the severity of disease, are absent in the pandemic A/2009/H1N1 virus (193) . Most virus strains have a truncated version of PB1-F2 that consists of 11 amino acids. Three isolates of the A/2009/H1N1 virus were reported to have PB1-F2, which consisted of 57 amino acids and was associated with an improvement in in vitro replication (421) . In cell culture and in an animal model, the introduction of various virulence-associated mutations into PB2 generally did not enhance the viral titer or virulence of the A/2009/H1N1 virus (252) . The only consistent viral signature associated with clinical severity, higher viral titer, and virulence in animal models is the D222G mutation (Table 1) , which is likely due to its high affinity for binding to ␣-2,3-linked sialic acid receptors in the lower respiratory tract. However, these mutants may have diminished transmissibility between the upper respiratory tracts from host to host, which may have selected against their prevalence. A comparison of the influenza viruses from different origins found that the residues E14 and F55 in the M2 proteins were predominantly in the human influenza virus but not in the swine or avian influenza viruses, suggesting that these residues may be important in human-to-human transmission (427) . The M1 protein has been shown to be essential in the high transmissibility of the A/2009/H1N1 virus in a guinea pig model (118) . Furthermore, a genomic analysis of the A/2009/H1N1 strains that were collected during the early prepandemic period showed that there have been multiple changes in the viral genome (382) , and several mutations in NP (V100I), NS1 (I123V), N (V91I and N233D), and H (S206T) have emerged as the predominant type, from fewer than 11% of the strains collected from April 2009 to more than 75% of the strains collected from June to December 2009 (426) . Because most of these mutant residues were located in the functional domain, it was proposed that these changes may enhance human adaptation of the virus or its virulence.
EPIDEMIOLOGY
When the chronology of the 2009 pandemic was examined (Table  2) , it was found that there were many similarities with the severe acute respiratory syndrome (SARS) epidemic (105, 106, 109, 437, 438) , except that the 2009 pandemic was considered to be mild in the first wave (449) . The outbreak started in a developing country, Mexico, but the virus was first isolated in California, where the public health and laboratory infrastructures are well established (140) . Although a phylogenetic analysis strongly suggested that swine would be the immediate animal host from which the virus jumped into humans, the immediate virus precursor could not be detected by animal surveillance programs. However, in analogy to the bat SARS coronavirus (332), a more distant precursor virus was found in swine. Fortunately, for the SARS epidemic, the immediate precursor virus of the human SARS coronavirus was found in civets, which were later banned in wet markets to prevent the relapse of the SARS epidemic (216) . Paradoxically, the retrograde passage of the A/2009/H1N1 virus back into pigs was well documented with genetic reassortment (530) . Though oseltamivir resistance or D222G viral mutation associated with severe disease was reported within 9 months, the proportions were very low (372) . In contrast to the SARS coronavirus, which could be controlled by infection control measures and social distancing, the A/2009/H1N1 virus rapidly infected over 40% of the susceptible population and became endemic by replacing the previously circulating human seasonal H1N1 virus.
Animal Surveillance
The scientific community anticipates that a future influenza pandemic is likely to originate from animals; however, many scientists were surprised that the 2009 pandemic may have originated from swine (481) and not from avian populations, which had been severely affected by the H5N1 and H9N2 viruses since 1997, with occasional poultry-to-human transmission (25, 52, 103, 104, 214, 215, 439, 440, 576) . In the prepandemic period, intensive screening was dedicated to poultry surveillance, especially in East Asia, where the lethal H5N1 first emerged (94, 214, 215, 351, 576) and where antigenically drifted H3N2 strains often emerged and spread throughout the world (462) . There were several warning signals for the 2009 pandemic. First, a triple-reassortant swine influenza H1N1 virus that represented a major antigenic shift event, composed of genomes from the H1N1, H3N2, and H1N2 viruses, emerged in the swine population in the late 1990s (417) . Second, this reassortant virus repeatedly jumped the species barrier and caused sporadic cases in humans, with 20% of these cases requiring invasive mechanical ventilation (408, 472) . Increased surveillance of pigs was proposed immediately before the pandemic (212) . However, the vast geographic extent of pig farming, especially in developing areas, makes pig surveillance difficult.
Mathematical Modeling
Mathematical modeling has been widely used to predict the spread of influenza virus and the effectiveness of containment strategies (342) . Although it is useful as a conceptual model, prepandemic modeling assumed that the pandemic began in Southeast Asia (120, 174) . During the current pandemic, realtime predictions of the spread of the pandemic have been performed but with only modest accuracy (19, 176) . Mathematical modeling can estimate the worst-and best-case scenarios to gauge the magnitude of the pandemic only when a sufficient caseload is available to calculate the basic parameters for the modeling. However, the interval for data accumulation has diminished the predictive value of mathematical modeling and its impact on epidemiological control. There have been few examples of policy changes or epidemiological controls that were based directly on the findings of mathematical modeling.
Epidemiological studies of laboratory-confirmed cases of 2009 pandemic influenza (Table 3) showed that for community outbreaks, the clinical attack rate ranged from 5.4% to 20.6%, the reproductive number ranged from 1.1 to 3.1, the generation time ranged from 0.8 to 3.9 days, and the incubation period ranged from 2 to 5 days (20, 36, 65, 134, 154, 184, 205, 226, 262, 359, 416, 506, 543, 556, 558, 571) . These figures did not differ from those in the epidemiological settings of households, schools, hospitals, and tours. No clear differences were observed in the studies conducted across different continents.
Seroepidemiology
Seroepidemiological studies have demonstrated that children and young adults were seronegative before 2009 and were more commonly infected than the elderly after the first wave (387) . Compared with patients with seasonal influenza, those with the A/2009/H1N1 virus were younger and less likely to have underly- (356, 563) . However, the preexisting seropositivity rate alone cannot explain some of the observations. For example, a study in Hong Kong showed an absence of preexisting seropositivity in the age group of 61 to 70 years, but the incidence of the A/2009/H1N1 virus was low in this population (579) .
Risk Factors for Severe Disease
In addition to extremes of age and chronic underlying medical illness, other risk factors for severe disease or complications emerged from the A/2009/H1N1 pandemic. Immunosuppressive therapy was reported in a greater percentage of fatal cases in North America than of fatal cases in Asia and the Far East (15.7% versus 6.1%; P Ͻ 0.001) (127, 152, 170, 181, 187, 305, 313, 365, 435, 574) (Table 4) . Additionally, underlying neurological conditions appeared to be more common in fatal cases in North America (37.7% versus 6.7%; P Ͻ 0.001) (127, 152, 181, 281, 305, 365, 435, 493, 523, 574) . Unexpectedly, obesity emerged as a new risk factor for severe influenza, which can predict mortality (364, 458, 522) .
Although obesity adversely affects pulmonary function, it has recently been associated with immunodysregulation involving adipokines (269, 298, 407) . Pregnancy has been confirmed as a risk factor for severe influenza (363) . Pregnant women who were infected during the third trimester were at a higher risk for complications. Notably, no deaths were reported in pregnant women in Asia and the Far East (305) . In a mouse model, pregnancy was associated with severe pulmonary damage and cytokine dysregulation, but there was no involvement of the placenta or fetus (85) . In addition, smoking and allergies have been proposed as risk factors, but no systematic control studies have been performed (233, 570) . In children, neurodevelopmental disorders emerged as a predominant risk factor (8) . Additionally, an IgG2 subclass deficiency has been linked to severe pandemic influenza, especially in pregnant women (80, 206) , and lower IgG2 levels in severe disease may be associated with cytokine dysregulation (80) . However, the usefulness of intravenous immunoglobulin replacement therapy still needs to be confirmed in randomized controlled trials (207) . Primary viral pneumonia is typically seen in patients with underlying comorbidities, such as chronic cardiopulmonary diseases, but 12.5% and 6.3% of cases occur in healthy adults and pregnant women, respectively (455) . Genetic susceptibility may predispose healthy individuals to severe disease. In a case-control study, single nucleotide polymorphisms (SNPs) in the genes encoding the FcyRIIA protein, the replication protein A-interacting protein, and the complement component 1q subcomponent binding protein and another gene in chromosome 3 were associated with severe pneumonia (591) . Interestingly, the SNP in the FCGR2A gene was found more frequently in patients with severe A/2009/H1N1 infection in China; however, this finding was not statistically significant (80) . Recently, a genome-wide knockdown study with a short hairpin RNA (shRNA) library identified several important host genes that are involved in the viral life cycle, including fusion, uncoating, transport of the viral RNP complex into and out of the nucleus, replication, transcription and translation of the genome, assembly, and budding (297, 319, 468) . The relationship between these host genes and disease severity should be examined further.
HISTOPATHOLOGY AND PATHOGENESIS
A total of 250 autopsies that examined the lungs, livers, spleens, and bone marrow specimens from 2009 pandemic H1N1 cases were reported in the literature (66, 200, 236, 378, 398, 403, 442, 470, 486, 500) . Among 190 fatal cases for whom clinical data were reported, the male-to-female ratio was 101:89. The ages ranged from 2 months to 83 years, with a median age of 35 years (66, 200, 236, 378, 398, 403, 470, 486, 500) . The interval between symptom onset and death ranged from 1 to 44 days, with a median of 8 days.
The histopathological changes in fatal cases depended on the date of death after symptom onset. The changes in patients who died within the first 10 days after symptom onset were dominated by virus-induced cytolysis and acute inflammation, which involved the upper to lower respiratory tracts. The changes in patients who NA a AR, attack rate (percent); R o , basic reproduction number, defined as the number of secondary infections generated by a primary infection in a susceptible population and which thus measures the intrinsic transmissibility of an infectious agent; T g , disease generation time, defined as the mean time interval (days) between infection of one person and infection of the people whom individual infects; NA, not available; NM, not mentioned. b In a retrospective analysis of the national surveillance data involving over 2,000,000 cases of A/2009/H1N1 influenza in Japan, it was noted that males Ͻ20 years of age may be more likely to suffer from A/2009/H1N1 than females in the same age categories (167) . c -, the attack rate in one study was highest among children aged 5 to 14 years (147 per 100,000 population), followed by children aged 0 to 4 years (113 per 100,000). The attack rate for children aged 5 to 14 years was 14 times higher than that for adults aged Ն60 years. d Outbreak among tour group members in China. e Outbreak on a passenger aircraft; their seating was within two rows of infected passengers, implying a risk of infection of about 3.5% for the 57 passengers in those rows. f Including an outbreak on a docked Navy ship in the United States, an outbreak at the U.S. Air Force Academy, and an outbreak on a Peruvian navy ship in the United States. died much later with intensive care support were dominated by both damage and reparative processes.
Histopathological Changes in the Respiratory Tract
Upper and middle airway infections caused by the A/2009/H1N1 virus were characterized by the multifocal destruction and desquamation of the pseudocolumnar and columnar epithelia, with significant submucosal edema and hyperemia to the extent of thrombus formation at the bronchiolar level. The acute inflammation could be severe, as evidenced by hemorrhagic tracheobronchitis and desquamative bronchiolitis with necrosis of the bronchiolar wall. Once necrosis occurred, there was infiltration by polymorphs and mononuclear cells. The histological changes in influenza pneumonia included interstitial edema with inflammatory infiltrate, alveolar proteinaceous exudation with membrane formation, capillary thrombosis, necrosis of the alveolar septa, intra-alveolar hemorrhage, desquamated pneumocytes with pyknotic nuclei into the alveolar spaces, and diffuse alveolar damage with dominant mononuclear interstitial infiltration by lymphocytes and histiocytes ( Fig. 4A and B) (200, 378, 470) . During the late stage, organizing diffuse alveolar damage, fibrosis, type II pneumocyte hyperplasia, epithelial regeneration, and squamous metaplasia were found, which are compatible with the fibroproliferative phase of acute respiratory distress syndrome (ARDS) and diffuse alveolar damage (Fig. 4C) . Histochemical staining for the viral NP showed that type II pneumocytes were the predominantly affected cell type (470) , and the staining was positive in patients who died within 3 days after symptom onset. Bacterial coinfections were documented in 26% to 33.3% of the case series that were analyzed (Fig. 4D) (66, 200, 236, 378, 470) . The most common bacteria found in the autopsy series included Streptococcus pneumoniae, Streptococcus pyogenes, Staphylococcus aureus, community-associated methicillin-resistant S. aureus, Streptococcus mitis, Haemophilus influenzae, and Acinetobacter baumannii (66, 107, 236) . Mouse studies suggested that during A/2009/H1N1 infection, the innate defense against secondary pneumococcal infection was impaired due to the increased gamma interferon (IFN-␥) response during the recovery stage of infection (496) .
Histopathological Changes in Extrapulmonary Sites
In addition to the pulmonary pathologies, the autopsy studies revealed pathological changes in other sites. Myocarditis with myofibril degeneration and interstitial lymphocytic infiltrate were found in several fatal cases of 2009 pandemic H1N1 infection (Fig.  4E) (195, 510) . Hemophagocytosis was found in several severe cases, as in cases of influenza A H5N1 virus infection (236, 470, 510) . Pulmonary thromboembolism was evident in 32 cases ( Fig.  4F and 4G) (200, 236, 378, 470, 510) . Splenic infarction associated with thrombosed arterial supply was observed in the postmortem examinations (Fig. 4H) .
Host Cytokine Profile
The majority of the studies on the blood cytokine and chemokine levels showed that interleukin-6 (IL-6), IL-8, IL-10, IL-15, IFN-␥, and tumor necrosis factor alpha (TNF-␣) were consistently elevated in severe disease (Table 5) . Although the blood IL-17 level was found to be elevated in one study (31) , this finding was not consistent and could be related to the sampling times at the different stages of the disease process (13, 225, 308, 510) . IL-17 has recently been shown to be important in the recruitment of B cells (536) . In vitro studies of the mRNA expression profiles and cytokine activation levels in virus-infected peripheral blood mononuclear cells showed no significant differences between the A/2009/ H1N1 and seasonal H1N1 viruses except for the downregulation of zinc finger proteins and small nucleolar RNAs by seasonal H1N1 virus (341) . The cytokine activation findings in animal challenge experiments with mice, ferrets, and macaque monkeys were heterogeneous, as expected with species variations (28, 85, 274, 294, 461) .
Host Immune Response
Upon infection, influenza virus will trigger a series of host immune responses. The initial innate immune response includes the following: the expression of pattern recognition receptors (PRRs), such as Toll-like receptors (150) , the retinoic acid-inducible gene I (RIG-I) protein (443) , and NOD-like receptors; the complement cascade; and antimicrobial peptides. The subsequent adaptive immune response consists of B and T lymphocytes, which are triggered by antigen-presenting cells, such as dendritic cells and macrophages.
Studies with prototype strains of the influenza A H1N1 virus showed that the virus triggers an immediate response from the innate immune system through nonspecific PRRs, including TLR3, -7, and -9 (150, 220) , at the plasma membrane or within endosomes. TLR3 recognizes double-stranded RNA (dsRNA); however, it is unclear whether the influenza virus produces dsRNA in infected cells. TLR7 and TLR8 recognize uridine-rich sequences of single-stranded RNA (ssRNA). The triggering of these TLRs will lead to the recruitment of MyD88 and the activation of transcription factor NF-B and mitogen-activated protein kinase (MAPK) inflammatory cascades. After virus entry and uncoating, viral RNA is recognized by the cytoplasmic RIG-I-like receptors, and the melanoma differentiation-associated gene 5 (MDA5), which are regulated by LPG2 and ubiquitin ligase (299) . A dsRNA binding protein, called PACT, is a potent binder and activator of RIG-I and boosts the antiviral interferon response (316, 352) . The activation of RIG-I results in a type I interferon response in epithelial cells. However, one key virulence factor of influenza virus, NS1, can inhibit this RIG-I-dependent interferon production in two ways. First, NS1 can interfere with the activation of RIG-1 by viral ssRNA harboring free 5=-triphosphate groups (443) . Alternatively, NS1 reduces RIG-I signal transduction by inhibiting the TRIM25-mediated RIG-I-CARD ubiquitination (190) . The significance of these molecular interactions between the viral and host factors is shown in cell culture and mouse challenge models infected with the prototype influenza A H1N1 virus (PR8). Compared with the PR8 virus with NS1 deleted, the cells and mice infected by the wild-type virus do not mount an innate immune response for almost 2 days postinfection as indicated by cytokine and chemokine assays and histopathology, during which the viral load starts to peak. This quiet stealth phase was followed by a sudden burst of lung inflammation in mice, with the subsequent initiation of adaptive immunity by migratory lung dendritic cells (390) . These findings are compatible with the clinical findings that the nasopharyngeal viral load in infected human volunteers had already peaked by the time the patients had symptoms (244) . It is unknown whether severe or fatal cases had a higher peak viral load because the majority of them did not present early; however, viral load monitoring after patient admission showed that patients had a delayed clearance of viral load in respiratory specimens, with concomitantly higher serum proinflammatory cytokines and chemokines (510) . Recently, it has also been shown that agonism of sphingosine-1-phosphate signaling in the endothelium could suppress the influenza virus-induced cytokine storm, suggesting the role of endothelial cells in the modulation of inflammation triggered by influenza virus (504) . It is possible that the final clinical outcome of the host was determined by the balance between the amount of tissue damage due to virusinfected cells, which is governed by the innate immune control and the subsequent adaptive immune control, the inflammatory damage inflicted by the innate immune response and the subsequent adaptive immune response, the pulmonary reserve, and regenerative power of the patient.
Infection by the A/2009/H1N1 virus may sometimes induce broadly reactive neutralizing antibodies that target the H stalk and globular head domain in multiple influenza virus strains. In addition, A/2009/H1N1 infection induced a cytotoxic T lymphocyte response that targeted internal type-specific viral core proteins (211, 555) . However, patients with severe influenza were shown to have lower serum complement levels and higher titers of antibodies, with a lower avidity for attaching to H, than those with mild cases (391) . The immune complex formed between low-avidity antibodies and viral antigens in infected cells fixed complement, which activated the inflammatory cascade and led to the exaggerated inflammation of infected lung tissue. This finding revealed a new phenomenon of pathogenesis for pandemic A/2009/H1N1 influenza virus (391) , which requires further confirmation.
Many studies have been conducted on the cross-reactive T lymphocyte-mediated immunity directed against both the A/2009/ H1N1 and seasonal H1N1 viruses ( Table 6 ). The amount of crossreactivity varied from 18.1% to 69% and was directed mainly against the internal proteins, such as M1, NP, and PB1 (213) . The prevalence of cross-reactive antibodies against the A/2009/H1N1 and seasonal H1N1 viruses in the sera of healthy individuals younger than 65 years of age was generally less than 6% before 2009 (77) . When these healthy individuals were immunized with the seasonal H1N1 vaccine, up to 22% of these vaccinees had a protective neutralizing antibody titer (232) . When mice were immunized with the seasonal H1N1 live attenuated vaccine, decreased morbidity and mortality were observed (92) . This protection was largely due to cell-mediated immunity.
Using flow cytometry, increased regulatory T (Treg) lymphocyte activity was observed in peripheral blood samples from infected versus noninfected patients at 1 to 2 days after symptom onset, but the increase was more significant in moderate cases than in severe cases (222) . In severe cases, B lym- phocytes were increased, T cells had impaired effector cell differentiation and proliferation, and there were fewer NK cells (Table 7) .
CLINICAL MANIFESTATIONS
Similar to the case for seasonal human influenza, which is a common cause of acute upper and lower respiratory tract infections in community and health care settings, A/2009/H1N1 disease ranges from a febrile upper respiratory tract infection to fulminant primary viral pneumonia or secondary bacterial pneumonia with ARDS, requiring intensive care and respiratory support. A study demonstrated that patients who subsequently developed ARDS and succumbed had a slower decline in nasopharyngeal viral loads, had higher plasma levels of proinflammatory cytokines and chemokines, and were more likely to have viremia, bacterial coinfections, or a complication of myocarditis than patients who had mild disease or who survived with ARDS (510) . Other studies demonstrated that pneumococcal coinfection played a similar role in causing mortality (200, 378, 423) as it did during the Spanish flu (112) . The clinical features of A/2009/H1N1 influenza virus infection were similar to those of seasonal influenza (Table 8) . However, there were notable differences between the fatal cases reported in North America and those in Asia (Table 4 ). The incidences of diarrhea (23.7% versus 4.3%; P Ͻ 0.001) and myalgia (40.9% versus 13.3%; P Ͻ 0.001) were significantly higher in North American patients. Regarding hospitalized patients, significantly higher rates of admission to intensive care units (ICUs) (P Ͻ 0.001), mechanical ventilation (P Ͻ 0.001), and death (P Ͻ 0.001) were observed in North America than in Asia (chi-square test) ( (Table 10) (42, 49, 61, 224, 323, 370, 376, 419, 485, 510) . These manifestations included hepatitis, myocarditis, rhabdomyolysis, renal failure, systemic or pulmonary vascular thrombosis, reactive hemophagocytosis, and, in children, acute necrotizing encephalopathy or encephalopathy. Renal failure was associated with an increased risk of death. Several of these manifestations were similar to those found in patients with H5N1 infection. Influenza-associated encephalopathy has been associated with thermolabile carnitine palmitoyltransferase II variants. The disease can be rapidly fatal within 1 to 4 days of acquisition (370) .
CLINICAL MANAGEMENT AND LABORATORY DIAGNOSIS
There are no pathognomonic signs and symptoms of influenza virus infections (169, 511) . The clinical, routine laboratory and radiologic findings are not distinguishable from those associated with other causes of influenza-like illness, severe community-acquired pneumonia, or ARDS (577). Patients with risk factors for severe disease who present with a nonsevere influenza-like illness may be managed as outpatients while waiting for the results of laboratory investigations. A chest radiograph should be performed if pulmonary involvement is suspected. The decision for hospitalization is based on the clinical assessment of disease severity, whether the patient can be readily followed up, and the risk factors for severe influenza infection. Patients with risk factors for severe disease should be empirically treated with oseltamivir or zanamivir, and patients with severe pneumonia should be treated with oseltamivir and broad-spectrum antibacterials for typical and atypical bacterial pneumonia (e.g., a ␤-lactam plus a macrolide). Influenza-like illness is clinically defined by the abrupt onset of fever and respiratory symptoms, such as rhinorrhea, sore throat, and cough, often with myalgia or headache; therefore, the specificity of this clinical definition can be as low as 10% during noninfluenza seasons and as high as 80% during an outbreak period. Additionally, the syndrome can be caused by other respiratory viruses, such as parainfluenza virus, enterovirus, adenovirus, and metapneumovirus, and several atypical bacteria, which can be differentiated only by laboratory testing.
Specimen Collection
The best specimen for a laboratory diagnosis should contain a high viral titer and a large number of infected cells. The yield is best when the specimens are collected within the first 2 to 3 days after the onset of symptoms during the peak of viral shedding in the respiratory tract (509) . Aerosol-generating procedures for specimen collection should be performed using proper infection control measures with droplet precautions and eye shielding. The first specimen should be collected before the commencement of antiviral therapy whenever possible. For upper respiratory tract specimens, a nasopharyngeal aspirate, nasopharyngeal flocked swab, nasopharyngeal rayon swab, nasal wash fluid, throat wash fluid, or throat swab can be collected, in descending order of sensitivity (409) . Lower respiratory tract specimens, including sputum, endotracheal aspirate, and bronchoalveolar lavage fluid, may be more sensitive in some cases with predominantly lower respiratory tract involvement (35) . Additionally, influenza virus may be detected in blood, stool, or urine (509, 510, 516) . Besides respiratory specimens, fecal specimens should also be collected in a viral transport medium, such as Hanks' balanced salt solution supplemented with 0.5% bovine serum albumin or 0.1% gelatin and antibiotics. Although the viral titer decreases with storage, the virus can usually be recovered by cell culture if it is maintained in a viral transport medium at 4°C for up to 5 days. A longer period of storage requires a temperature of Ϫ70°C to maintain viral viability (21) .
Nucleic Acid Amplification
RT-PCR diagnostic tests are often targeted against the M gene, which is abundant and genetically conserved, and the H gene, which is abundant and subtype specific (153, 331, 447) . The most useful laboratory test for the clinical management of A/2009/H1N1 influenza is nucleic acid amplification after reverse transcription (Table 11) . In 10 studies, the overall reported sensitivity of real-time RT-PCR ranged from 90.5% to 97.6% (60, 202, 240, 286, 321, 336, 404, 422, 432, 559) . The majority of the studies reported a specificity of 100%, with four exceptions (60, 404, 432, 559) . Many diagnostic laboratories and commercial vendors have rapidly responded to this pandemic by providing in-house or commercially packed real-time nucleic acid amplification assays.
Antigen Detection
All commercially available immunochromatographic assays for the detection of the viral NP can differentiate between influenza A and B viruses but not between the different subtypes. The reported sensitivities ranged from 11% to 83.7% with a median of 53.3%, which is significantly inferior to that of RT-PCR or viral culture. The specificities for immunochromatographic assays ranged from 96% to 100% (Table 12 ) (115-117, 144, 157, 171, 191, 201, 242, 309, 315, 497, 525, 526, 540) . Similarly, the direct immunofluorescent antigen detection test for the influenza virus NP had a sensitivity ranging from 38.7% to 92.8%, with a median of 64.9%, and a specificity of 94.5% to 100% (191, 202, 242, 446) . However, the testing of these exfoliated cells must be performed soon after specimen collection. The cells from specimens can be washed in cold buffer and treated with N-acetylcysteine to remove mucus before fixation onto slides (82, 83) . In some laboratories, the influenza A and B viruses, respiratory syncytial virus (RSV), adenovirus, and parainfluenza (PIF) 1, 2, and 3 viruses are concurrently detected in a common pool before a monoclonal antibody is used to differentiate the respiratory virus that is present (82, 83) .
Viral Culture
The gold standard for the diagnosis of influenza virus relies on a positive culture of the respiratory secretions in cell lines, such as the Madin-Darby canine kidney (MDCK) or rhesus monkey kidney cell line, in the presence of trypsin (329) . Most continuous cell lines do not produce proteases that cleave H to make infectious viral progeny, with the exception of Caco2 cells, which can produce trypsin-like proteases (349) . Tosylsulfonyl phenylalanyl chloromethyl ketone (TPCK)-treated trypsin at 1 to 2 g/ml is added to the cell culture medium. TPCK treatment will inactivate the chymotrypsin in a pancreatic extract, whose proteolytic activity on H will nullify the trypsin-mediated enhancement of viral infectivity. Fetal calf sera contain inhibitory factors that must be removed by washing with Hanks' buffer prior to infection. Incubation with serum-free culture medium with trypsin at 33 to 35°C will usually produce a cytopathic effect within 1 to 7 days. Additional strains may be recovered with prolonged incubation of up to 14 days after one blind passage. The interval between inoculation and detection ranges from 2 to 14 days, with a median of 3 to 5 days (346). The R-mix cell line (a mixture of mink lung and A549 cell lines) was reported to have a sensitivity of 88.9%, whereas the MDCK cell line had a sensitivity of only 45.7%, compared with real-time RT-PCR as the gold standard (191) . In addition to identifying the microscopic changes of cytopathic effects, positive cultures can be detected by hemadsorption. Influenza virus isolates can be typed as type A or B and subtyped by immunofluorescence. In contrast to nucleic acid amplification, antigen detection, and antibody assays, viral culture is less affected by genetic or antigenic changes. Cell culture had a specificity of nearly 100% (191, 202) .
Antibody Testing
The detection of specific antibodies in serum may be used when the specimens for viral isolation or RNA or antigen detection are negative, inadequate, or unavailable. Antibody testing has detected up to one-third of severe cases admitted to ICUs when the RT-PCR results were negative (277) . However, this testing cannot differentiate different lineages of the same subtype of the influenza A virus. The majority of individuals have already been exposed to the seasonal influenza A virus, which has almost identical NP and matrix protein sequences; therefore, a 4-fold rise in the complement fixation antibody titer with these antigens indicates a recent influenza A virus infection without differentiating between seasonal H1N1 or H3N2 infection and the pandemic 2009 H1N1 infection (14) . Although recombinant H has been found to be sensitive and specific for antibody detection by EIA, cross-reactivity between seasonal H1N1 and pandemic H1N1 may still occur, because their overall amino acid identity was 80.1% for H (440 out of 549 amino acids), 72% for HA1, and 92% for HA2 (Fig. 1) . Therefore, IgG and IgM detection by EIA is generally not useful, except in the case of avian H5N1 infection in humans, where recombinant H5 was used in a Western blot immunoassay (44) . The traditional gold standard techniques for detecting influenza virusspecific antibodies are neutralization and hemagglutination inhibition assays, which may detect subtype-specific or lineage-specific serological responses. Human influenza viruses can agglutinate turkey, human, and guinea pig erythrocytes; however, most laboratories routinely use turkey erythrocytes for hemagglutination inhibition antibody tests. Turkey erythrocytes are small and nucleated and sediment quickly, producing a clear and reproducible endpoint. Turkey erythrocytes express a mixture of ␣-2,3-and ␣-2,6-linked sialic acid receptors and can be used for the detection of antibodies against either human or avian influenza viruses, whereas the avian influenza A H5N1, H9N2 and H7N7 viruses agglutinate horse erythrocytes, which almost exclusively express ␣-2,3-linked sialic acid receptors (273) . Antibody levels accurately correlate with protection from (or susceptibility to) disease and vaccination status (84) . A definitive serological diagnosis of acute influenza requires the demonstration of a 4-fold increase in antibody titers on paired acute-and convalescentphase serum samples. A seroprevalence study using the hemagglutination inhibition test was useful in 2009 when the population was immunologically naïve except for elderly patients, who may have been previously exposed to the 1976 swine influenza virus or the 1918 Spanish influenza virus, both of which have cross-reactivity to the A/2009/H1N1 virus (45). Since changes in the H proteins of influenza A H3N2 and influenza B viruses have markedly diminished their ability to agglutinate avian erythrocytes, including turkey erythrocytes since late 1990s, the neutralizing antibody test may be a better option for these viruses.
Though it is more labor-intensive and still could be confounded by cross-reactivity, the neutralizing antibody test is often considered the gold standard serological test for immunity against different strains of influenza virus. A retrospective analysis of the serum antibody responses assayed by neutralizing antibody titers against the A/2009/H1N1 virus in 881 convalescent patients demonstrated that 90% of them had a seroprotective titer of 1:40 or above (265) . A multivariate analysis by ordinal regression showed that pneumonia and sputum production were two independent factors associated with higher levels of convalescent-phase neutralizing antibody titers. Patients who were afebrile on presentation were associated with a subsequent poor neutralizing antibody titer (Ͻ1:40). A positive correlation between the nasopharyngeal viral load on presentation and the convalescent neutralizing antibody titer was demonstrated. Convalescent patients with a high neutralizing antibody titer were suitable candidates for the donation of plasma for passive immunotherapy (265) .
Antiviral Susceptibility Testing
Viral susceptibility to adamantanes can be detected by standard cell protection assays, whereas the inhibition of the enzymatic activity of N is the most sensitive and specific phenotypic means of detecting resistance to neuraminidase inhibitors, such as oseltamivir, peramivir, and zanamivir. The standard methods for detecting antiviral resistance based on changes in the viral phenotype in cell culture, such as the plaque reduction and yield reduction assays, were not reliable for the detection of clinical isolates resistant to neuraminidase inhibitors (217, 218) . The contradictory findings from cell culture-and enzymatic activity-based assays suggested that the H of clinical isolates may bind suboptimally to the ␣-2,3-linked sialic receptors of the MDCK cells used in cell protection assays, because human influenza viruses bind preferentially to ␣-2,6-linked sialic acid. When H binds with a lower affinity to MDCK cell receptors, the virus is less dependent on the neuraminidase activity of N for its release; therefore, the virus appears to be less sensitive to neuraminidase inhibitors in vitro. Zanamivir susceptibility in animal challenge models correlated well with in vitro susceptibility as determined by the neuraminidase inhibition assay but not by the plaque reduction assay in MDCK cells (507) . The majority of laboratories currently use a phenotypic assay with chemiluminescent or fluorescent substrates (NAStar; Applied Biosystems, Foster City, CA) to detect the susceptibility of the enzymatic activity of N to neuraminidase inhibitors.
A rapid genotypic assay for the detection of mutations causing resistance against adamantanes and neuraminidase inhibitors can be performed by standard PCR sequencing and, more recently, by pyrosequencing without the need for viral culture (324) . Multiplex PCR can simultaneously detect the presence of the A/2009/ H1N1 virus and the mutations responsible for the resistance (29, 368) . Methods that can detect the resistant strains among a mixed population include pyrosequencing (146) , high-resolution melting curve analysis (102) , and, in research laboratories, deep sequencing (197) . Other methods include RT-PCR and the restriction fragment length polymorphism assay (415) . However, pyrosequencing can detect the emergence of resistant quasispecies in treated individuals without laborious cloning and Sanger sequencing. The clinical significance of viral quasispecies in drug resistance is undetermined except in immunosuppressed hosts in whom resistant viral quasispecies have emerged early in treatment (22) . In this group of patients, prolonged viral carriage and shedding provided an opportunity for the viruses to pick up compensatory mutations that maintain the resistance after selective drug pressure is removed.
ANTIVIRAL AND IMMUNOMODULATORY THERAPIES

Antiviral Treatment
The antivirals against influenza A virus that are currently available and commonly used include the adamantanes (amantadine and rimantadine) and neuraminidase inhibitors (oseltamivir, zanamivir, and peramivir), but only the latter are active against the A/2009/H1N1 virus. Oseltamivir is available orally. Zanamivir is available either as a dry powder that is delivered by oral inhalation or, more recently, as an intravenous formulation. Nebulized zanamivir is useful in selected cases (135) . However, nebulization of the powder form of zanamivir that is dissolved in water has been found to clog the ventilator circuit and should not be used (179) . Intravenous peramivir was available only for compassionate use in the United States during the pandemic (34) . In addition to neuraminidase inhibitors, the traditional Chinese medicine maxingshigan-yinquaosan has been shown to hasten fever resolution in a randomized trial, but its action may be immunomodulatory rather than antiviral (534) . The role of other newer antivirals, such as nucleozin analogs (295) , the neuraminidase inhibitor CS-8958 (311), the polymerase inhibitors viramidine (474) and T-705 (312), and sialidase DAS181 (27) , requires further evaluation (243) . Combination therapy with the protease inhibitor aprotinin and other antivirals may be effective, but the side effects of aprotinin treatment, including stroke, heart attack, kidney failure, thrombosis, and anaphylaxis, must be considered (582) .
Randomized controlled trials with patients having seasonal influenza suggested that neuraminidase inhibitors shortened the duration of illness by approximately 1 day (245). However, most authorities would not recommend routine oseltamivir treatment for mild illness because of the risk of fostering drug resistance. For the A/2009/H1N1 virus, oseltamivir therapy has generally been associated with a faster resolution of symptoms and a more rapid clearance of viral shedding in hospitalized patients of all ages, organ transplant recipients, and pregnant women (350, 357, 575) (Table 13) . A longer delay of oseltamivir treatment in severe cases was associated with a poorer outcome (281, 574) because viral shedding in the respiratory tract peaks at 24 to 72 h after infection.
Since viral shedding is already substantial even before the onset of symptoms, the efficacy of treatment decreases sharply with any delay in antiviral administration.
Intravenous zanamivir and peramivir have been used in patients with severe disease (Table 14) . These antivirals have in vitro activity against the A/2009/H1N1 virus and have been beneficial in some cases; however, no randomized controlled trials or comparative clinical trials have been reported (238, 303) . Oseltamivirzanamivir combination therapy has not been studied in patients with A/2009/H1N1 influenza, but it has been found to be less effective than oseltamivir monotherapy for the treatment of seasonal influenza (161) . The optimal dosing for intravenous zanamivir is not known, but 600 mg every 12 h has been shown to be effective for oseltamivir-resistant strains of the A/2009/H1N1 virus in an in vitro hollow-fiber infection model (47) .
Ribavirin has been used for the treatment and prophylaxis of influenza (90) . The routes of administration include oral, intravenous, and aerosolization routes. Anecdotal reports have demonstrated the efficacy of this therapy against influenza A and B, including infections in immunosuppressed hosts. Unfortunately, a consistent benefit has not been observed in all of the clinical trials, and intravenous ribavirin is currently not considered a drug of choice for the treatment of influenza because of its toxicity. Similar to the case for inhaled zanamivir, inhaled ribavirin may not be able to penetrate the poorly aerated consolidations of pneumonic lungs.
Antiviral Resistance
All A/2009/H1N1 strains are resistant to adamantanes due to the S31N mutation in the M2 protein (79, 554) . Globally, oseltamivir resistance due to the H275Y (by N1 numbering) substitution in neuraminidase accounts for fewer than 2% of the strains tested (554) . In addition, H275Y strains are resistant to peramivir but remain susceptible to zanamivir. The differential antiviral susceptibility is due to the differences between the binding mechanisms of oseltamivir and zanamivir. The binding of oseltamivir to the active site of neuraminidase requires a conformational change, whereas this change is not required for zanamivir (395) . It is interesting to note that the in vitro triple combination of oseltamivir, amantadine, and ribavirin is highly synergistic against the A/2009/ H1N1 virus (411) .
Oseltamivir resistance has been reported in patients without prior exposure to oseltamivir (Table 15) , and it can develop quickly after oseltamivir treatment (272) . It is especially common in immunosuppressed hosts, in whom a higher viral load is expected due to the poor control by the host immune response. The nosocomial spread of an oseltamivir-resistant influenza virus has been documented in a clinical setting (392) . Other mutations (E119G, E119V, and I222V) have been found to confer oseltamivir resistance in vitro, but they have not been reported in clinical strains (445) .
The S247N mutation, which was found in 30% of the specimens from northern Australia, results in 6-fold and 3-fold reductions in susceptibility to oseltamivir and zanamivir, respectively (266) . Despite this low level of resistance in vitro, there were reports of clinical treatment failure (410, 521) . The combined S247N and H275Y mutations resulted in a Ͼ5,000-fold reduction in oseltamivir susceptibility. A structural analysis using computer modeling suggested that the S247N mutation pushes the E277 residue deeper into the drug binding pocket, resulting in reduced oselta-mivir binding. Additionally, the I223R and I223K substitutions in neuraminidase can result in reduced susceptibility to zanamivir (410, 521) .
There has been controversy regarding the fitness and virulence of resistant mutants. The H275Y mutation in the A/2009/H1N1 virus has been shown to reduce viral replication in vitro (46) . However, H275Y mutants were as virulent as wild-type viruses in mouse and ferret models, with no reduction in transmissibility (230, 383) .
Safety of Antivirals
Neuraminidase inhibitors are relatively safe. Reports from Japan suggested that oseltamivir may be associated with neurotoxicity in adolescents. Oseltamivir and its metabolites may have excitatory effects on the central nervous systems of rats, which may account for some of the neuropsychiatric side effects that have been observed in the past few years with more widespread use of the drug (278) . The safety of these agents in infants and pregnant women is unknown. Oseltamivir and zanamivir are currently approved for children over 1 and 7 years of age, respectively. Limited studies have demonstrated that oseltamivir is safe in infants under 1 year of age (136, 310) . Currently, there is no evidence that oseltamivir is teratogenic, but it is classified as FDA category C due to the lack of data. Additional safety data should be collected due to the increasing use of intravenous zanamivir and peramivir (54, 314, 495) .
Passive Immunotherapy
There is no definitive evidence that antivirals work in severe cases when patients present late after the onset of symptoms. Thus, modulation of the host immune response by dampening down the proinflammatory damage with steroids, statins, and macrolides has been studied (Table 16) ; however, none of these drugs were tested in the setting of a randomized controlled trial. Convalescent-phase plasma is another potentially useful form of therapy for severe influenza due to the influenza A virus. Convalescent-phase plasma has been used in one patient with A/H5N1 infection, with good clinical and virological responses (585) . A meta-analysis of the use of convalescentphase blood products during the Spanish influenza pandemic showed that there was a survival benefit in patients who received this treatment, and the benefit was greater if treatment was initiated within 4 days of the onset of pneumonia (367) . Based on these findings, a prospective cohort study was conducted on the treatment of patients with severe A/2009/H1N1 infection using convalescent-phase plasma collected from sur- viving patients (264, 557) . In this study, a number of practical limitations were encountered during the collection of convalescent-phase plasma by apheresis (548) . These limitations included the failure of donors to meet blood donation eligibility criteria, failed laboratory tests, insufficient neutralizing antibody titers, and the inability of donors to attend the apheresis appointment. Despite these limitations, 276 liters of convalescent-phase plasma were collected from more than 60% of the potential donors with sufficient neutralizing antibody titers. None of the patients in the treatment group developed adverse effects after convalescent serotherapy. The mortality in the treatment group was significantly lower than that in the nontreatment group. In addition, the reductions of viral load and the corresponding cytokine/chemokine were greater in the treatment group. These two studies demonstrated that passive immunotherapy was feasible (344) and that the treatment of severe A/2009/H1N1 infection with convalescent-phase plasma appeared safe and effective, which has important implications for treatment strategies using passive immunotherapy in future pandemics. However, these findings should be confirmed in randomized controlled trials. Broadly neutralizing antibodies against the stalk of H and the M2 ectodomain may be important in passive immunization. Humanized neutralizing anti-M2e monoclonal antibodies were shown to protect against lethal challenge by H5N1 and H1N1 viruses (210) . A monoclonal antibody that targeted the conserved F subdomain of HA2 has been shown to protect mice and ferrets from both H1N1 and H3N2 infections (122) . A randomized controlled trial of treatment with specific human monoclonal antibodies or hyperimmune intravenous immunoglobulin in patients with severe influenza infection is warranted.
Controversial Use of Steroids and Other Immunomodulators
The use of corticosteroids in the treatment of A/2009/H1N1 influenza is controversial because no randomized controlled trials have been conducted. Some studies have shown a beneficial effect of corticosteroids, whereas other studies showed no effect or even a detrimental effect (Table 16 ). One study demonstrated that the risk of death was higher in the corticosteroid group only in patients who received early administration of corticosteroids within 3 days of mechanical ventilation (48) . Case reports have indicated that therapy with etoposide and betamethasone was beneficial in a patient with hemophagocytic lymphohistiocytosis (251) . High-dose N-acetylcysteine has been shown to reduce the inflammatory response (327) . Statins that were started before or after influenza infection were not associated with better outcomes (43, 528) . Animal and cell culture models have suggested that agents such as paracetamol and mesalazine may reduce damage, but these findings remain to be confirmed in humans (334, 549, 581) . In mice, activation of the innate immune system by PIKA, a chemical analog of dsRNA, is associated with a reduction in viral replication in the respiratory tract (333) . Recently, an antiinflammatory immunomodulator, a sphingosine analog, was successfully used in combination with oseltamivir to improve the survival of A/2009/H1N1-infected mice by significantly blunting the cytokine storm and tissue injury. In contrast to steroids, this novel approach does not suppress the protective adaptive immune response of the host against the invading virus and is a more logical approach for treating patients with severe disease (532) . 
VACCINES
Despite the best available treatments, the mortality from severe A/2009/H1N1 infection is substantial. Prevention by vaccination is crucial. In addition to the prevention of pulmonary complications, influenza vaccination can prevent medical catastrophes triggered by influenza, such as myocardial infarction and stroke, especially when combined with pneumococcal vaccination (263) .
The greatest setback in the 2009 influenza pandemic was the nonavailability of the vaccine until late 2009 in most countries. Thus, the summer peak in tropical areas and the winter peak in the Southern Hemisphere during August 2009 passed before vaccines were administered. Innovations, such as cell-based whole-virion inactivated vaccines and dose-sparing adjuvants (17, 129, 519) , boosted the vaccine supply but were unable to shorten the interval between the first detection of the virus and the availability of the vaccine in the market (249, 479) . A hemagglutination inhibition titer of 1:40 has been achieved in more than 90% of vaccinees, although children less than 11 years of age or adults greater than 61 years of age had poorer responses (588) . Other factors that are associated with a poor response to vaccination include immunosuppressed states or chronic diseases. Adjuvants and two-dose regimens may improve immunogenicity. Dose sparing by the use of the intradermal route or new adjuvants was shown to have equivalent efficacy to that of a normal dose of vaccine (508) . Vaccine effectiveness, as defined by the reduction in the risk of laboratory-confirmed infection between vaccinated and nonvaccinated individuals, has been estimated to be approximately 70% (235) . It should be noted that live attenuated vaccines induce a lower antibody response in adults than inactivated vaccines (62), and vaccine recipients have had lower antibody titers than individuals with natural infection (84) . Prior seasonal influenza vaccination has been found to worsen the outcomes of patients with A/2009/H1N1 infection (283, 478) . The increased risk may be due to the lack of cross-reactive immunity induced by natural seasonal influenza infection (385) . However, other clinical studies have demonstrated contradictory findings, with no apparent increase in the severity of pandemic A/2009/H1N1 infection in individuals who received a prior seasonal influenza vaccine (126, 192, 289) . It has been shown that prior seasonal influenza vaccination can increase the levels of antibodies against neuraminidase in the elderly (374) . Furthermore, cross-reactive T cells induced by the seasonal influenza vaccine may confer some degree of protection against pandemic A/2009/ H1N1 infection (258) . The acceptance of the pandemic influenza vaccine is low, partly due to the concerns regarding safety, such as the development of Guillain-Barre syndrome after vaccination (330, 466, 467, 512) . Nevertheless, both premarketing trials and postmarketing surveys showed that the risk of developing Guillain-Barre syndrome in individuals who receive the pandemic influenza vaccine is similar to that in the general population (76, 353) .
INFECTION CONTROL IN THE COMMUNITY AND HOSPITALS
Before the emergence of the A/2009/H1N1 pandemic, nonpharmacological interventions with social distancing, such as school closures, had been evaluated in modeling (26, 175) and epidemiological (38, 125, 256, 375) studies. School closures were practiced in North America and Australia during the 2009 pandemic (40, 121, 165) because of a high clinical attack rate that ranged from 10% to 60% (133, 221, 248, 275, 347, 514) (Table 3) . School closures were associated with a 65% reduction in the mean total number of contacts for each student as reported in a retrospective questionnaire survey in the United Kingdom (279) . However, a late school closure in which 27% of the students already had symptoms had no significant impact on the spread of infection (63) . Therefore, school closures should begin once the threshold for daily case counts is exceeded (228) . In Hong Kong, kindergartens and primary schools were closed when local transmission of the A/2009/H1N1 virus was identified, followed shortly afterwards by secondary school closures for summer vacations. The transmission of the A/2009/H1N1 virus was estimated to be reduced by 25% (556) .
Household transmission of the A/2009/H1N1 virus was reported to have an attack rate of up to 45% (Table 3) (59, 64, 124, 182, 284, 318, 393, 428, 436, 550, 558, 571) . The transmissibility of the A/2009/H1N1 virus in the household setting was broadly similar to that of seasonal influenza A viruses (124) . The attack rate was highest among children and adolescents. Household contacts less than 18 years of age were approximately 15 times more likely to be infected than older contacts (348) . When oseltamivir was used as postexposure prophylaxis, the household secondary attack rate was reduced from 26.1% to 0.6% (318) . However, whether the early treatment of the index person with oseltamivir can reduce secondary infections in the household setting remains to be determined (203) . Hand hygiene and face masks appeared to prevent household transmission of influenza virus when implemented within 36 h of symptom onset in the index patient (123) . The wearing of face masks was well tolerated by children less than 14 years of age (494) . Frequent hand washing has been shown to reduce surface contamination by influenza virus in the household (475) . Simple nonpharmaceutical interventions may mitigate pandemic influenza if compliance can be ensured.
The nosocomial transmission of the A/2009/H1N1 virus was reported to have an attack rate of 10% to 45% in health care settings (531), including acute-care hospitals and long-term care facilities (10, 74, 114, 172) . Among the 30 patients who acquired A/2009/H1N1 infection during hospitalization in the United Kingdom, 8 (27%) of the patients died. Most of them had an underlying malignancy or immunosuppressive conditions (166) . For health care workers (HCWs), asymptomatic infection as evidenced by seroconversion was observed in 28 (9.6%) of 290 nurses, especially in nurses who worked in the isolation wards (100). Therefore, an infection control program that consisted of multiple coherent measures was proposed to minimize the nosocomial transmission of the A/2009/H1N1 virus during the early phase of the pandemic in Hong Kong. This program included several open staff forums that achieved high attendance, the early recognition of index cases among inpatients by liberal testing, the early relief of sick staff from work, directly observed hand hygiene practices during outbreaks, and the monitoring of compliance with infection control practices. With these measures, only 4 (0.48%) of 836 persons who were exposed to laboratory-confirmed patients and staff with A/2009/H1N1 infection were virologically confirmed to have A/2009/H1N1 infection. Not wearing a surgical mask, either by exposed persons during contact with index cases (4/4 versus 264/832; P ϭ 0.010) or vice versa (4/4 versus 300/832; P ϭ 0.017), was found to be a significant risk factor for the nosocomial acquisition of A/2009/H1N1 infection (108) . Additionally, this finding was observed in a study in Singapore that demonstrated that the incidence of pandemic A/2009/ H1N1 infection remained low in HCWs who wore surgical masks (10) . In contrast, surgical mask use was not consistently practiced in the United States, where the Centers for Disease Control and Prevention received reports of 70 HCWs with A/2009/H1N1 infection from 22 states. Of these cases, 35 (50%) were classified as being infected in a health care setting. Of the 23 HCWs infected by patients, only 20% reported using an N95 or surgical mask during all patient care practices (546) .
Good adherence to infection control practices may reduce potential occupational exposure to the A/2009/H1N1 virus in the hospital setting. In a seroprevalence study of the A/2009/H1N1 antibodies in 599 HCWs after the first wave in Hong Kong, only 12% of the HCWs who did not receive the pandemic vaccine had antibody titers of Ն1:40 as detected by a viral neutralization assay (587) . Influenza vaccination has been strongly advocated to protect both patients and HCWs, especially HCWs who work in ICUs with high-risk aerosol-generating procedures, such as intubation, resuscitation, and the delivery of aerosolized medications (138) . However, the A/2009/H1N1 vaccination uptake was less than 50% in a group of HCWs who worked in the critical care and theater settings in the United Kingdom (430) , whereas the A/2009/H1N1 vaccination rate of HCWs was just over 30% in France (503) but less than 20% in Spain and Italy (9, 145) . The A/2009/H1N1 vaccination uptake rate is higher in the United States. Among the HCWs who worked at a facility where vaccination was required by their employer, 98.1% were vaccinated, whereas only up to 70% of HCWs were vaccinated without this employer requirement (70) . In addition, a high level of acceptance with a voluntary uptake rate of up to 70% was observed in Canada (292) 
CONCLUSION
The lessons of the human pandemic of A/2009/H1N1 virus in 2009, the epidemic of SARS coronavirus in 2003, and the poultry epidemic of influenza A H5N1 virus since 1997 suggest that preparedness against agents of emerging infectious diseases that jump from animals to humans must continue. Rapid economic growth in many developing areas of the world has led to an increasing demand for animal proteins, such as pork. Large numbers of swine and other food animals are reared with antibiotic-loaded feeds in overcrowded conditions. Inadequate biosecurity measures allow for the continued jumping of novel influenza virus reassortants or multidrug-resistant bacteria from swine to humans. The potential combination of influenza and antibiotic-resistant bacterial infections could prove disastrous should future pandemics occur. Improved human and animal surveillance programs are essential for a rapid response against this occurrence. Currently, no bioinformatic or in vitro tests can reliably predict the virulence or clinical severity of potential new pandemic viruses. Transgenic humanized animal models should be investigated to address this important issue for better resource allocation.
The superiority of the nucleic acid amplification test has been demonstrated in the clinical management of A/2009/ H1N1 infection. A multiplex system coupled with microfluidic technology that uses a small amount of clinical samples can enhance the robustness and application of nucleic acid amplification in field settings. More antiviral agents that attack the different parts of the viral life cycle should be developed to overcome antiviral resistance. Novel immunomodulatory agents that dampen detrimental inflammatory responses without hindering the protective immune response of the host should be developed and tried in those late presenters with severe diseases due to overly activated cytokines and chemokines. In future pandemics, instead of waiting for a new vaccine that is based on the pandemic virus, heterologous protection should be achieved with a readily available universal vaccine that is based on the highly conserved stalk region of H and the ectodomain of M2. This universal vaccine will overcome the delay between the detection of the new virus and the availability of the vaccine in the market from mass production. Strategies that accelerate a vaccine-induced immune response should be developed. The influenza virus is highly unpredictable, and we should always be open-minded when facing the unknown.
